Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
QTQ32 Bio Inc. logo

Q32 Bio Inc. (QTTB)

NASDAQ Global Market · Currency in USD
$8.65 ▼ -0.15 (-1.70%)
At close: Oct 23, 4:00 PM ET. Market closed.
$8.65 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$8.80
Open
$8.80
Day's Range
$8.31 – $8.80
52 Week Range
$1.91 – $23.57
Volume
403,793
Avg. Volume
1,115,617
Market Cap
$257.51M
Beta (5Y Monthly)
-0.33
PE Ratio (TTM)
3.10
EPS (TTM)
$2.40
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$36.50

Profile: Q32 Bio Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
22
CEO
Jodie Pope Morrison
Website
q32bio.com

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.36
DateEst.Actual
Aug 5, 2026-$0.53-$0.44Beat
May 5, 2026-$0.68-$0.54Beat
Mar 10, 2026-$0.85$3.65Beat
Nov 13, 2025-$1.39-$0.60Beat
Aug 6, 2025-$1.14-$0.78Beat
May 8, 2025-$1.23-$0.90Beat

Analyst view

Consensus price target
$36.50 ▲ +322.0%
Range $14.00 – $66.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on QTTB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.